This article is more than 5 years old. Information may no longer be current.
Botox treats masseteric hypertrophy for at least 9 months
Click Here to Manage Email Alerts
VANCOUVER, British Columbia — Botox reduces muscle volume and improves lower facial contouring in those with masseteric hypertrophy, according to a poster presented at the 23rd World Congress of Dermatology.
In the study, 42 patients with masseteric hypertrophy received either 25 U, 30 U or 35 U of botulinum toxin type A (Botox; Allergan) depending on muscle thickness.
Masseteric muscle thickness greatly decreased from 3 to 9 months after injection from 12.25 mm to 11.35 mm and to 12.45 mm.
At 3 months, the mean percentage reduction of muscle mass for the 25 U, 30 U and 35 U were 15.45%, 16.20% and 13.89%, respectively.
The Masseteric Hypertrophy Severity (MHS) score decreased at 3 months and significantly decreased at 9 months postinjection at all three doses.
Researchers found a low positive correlation between baseline MHS score and baseline masseteric muscle thickness.
The researchers wrote that the clinical square face may be due to other components such as subcutaneous fat, bone or parotid gland.
Three-quarters of the patients were satisfied with the treatment and there were no serious adverse effects.
Reference :
Panchaprateeep R, et al. Botulinum toxin type A injection for masseter hypertrophy: Efficacy and duration of treatment determined by ultrasonography and masseteric hypertrophy severity score. Presented at: 23rd World Congress of Dermatology; June 8-13, 2015; Vancouver, British Columbia.